RX Product News

Published Online: Friday, October 5, 2012
Follow Pharmacy_Times:

Auvi-Q
Marketed by: sanofi-aventis US LLC (Bridgewater, NJ)
Indication: Auvi-Q (epinephrine injection, USP) is a nonselective alpha- and beta-adrenergic agonist indicated for the emergency treatment of allergic reactions, including anaphylaxis. It is the first and only auto-injector that features audio and visual cues that guide patients and caregivers through the injection process. Each single-use injector can be used intramuscularly or subcutaneously in the anterolateral aspect of the thigh, through clothing if necessary. Dosage is based on patient weight.
Dosage Form: Pre-filled auto injectors: 0.3 mg (0.3 mg/0.3 mL epinephrine injection, USP) and 0.15 mg (0.15 mg/0.15 mL epinephrine injection, USP)
For More Information: www.auvi-q.com



Aubagio
Marketed by: Genzyme, a Sanofi company (Cambridge, MA)
Indication: Genzyme, a Sanofi company, announced the FDA approval of Aubagio (teriflunomide), a pyrimidine synthesis inhibitor indicated for patients with relapsing forms of multiple sclerosis. Aubagio is a once-daily oral treatment that can be administered with or without food. The product carries a boxed warning describing risks of hepatotoxicity and teratogenicity, and is contraindicated in patients with severe hepatic impairment and those who are pregnant, as well as in patients currently taking leflunomide.
Dosage Form: Film-coated tablets: 7 and 14 mg
For More Information: www.aubagio.com



Xtandi
Marketed by: Medivation, Inc (San Francisco, CA) and Astellas Pharma Inc (Tokyo, Japan)
Indication: The FDA approved Xtandi (enzalutamide) for the treatment of patients with metastatic castrationresistant prostate cancer who have previously received docetaxel. An androgen receptor inhibitor, Xtandi is being distributed through specialty pharmacies and specialty distributors with a patient access support program called Xtandi Access Services. The dosage of Xtandi is 160 mg given as four 40-mg capsules once daily, taken with or without food, and capsules must be swallowed whole.
Dosage Form: Capsule: 40 mg
For More Information: www.xtandihcp.com; www.xtandiaccess.com



Linzess
Marketed by: Ironwood Pharmaceuticals (Cambridge, MA) and Forest Laboratories, Inc (New York, NY)
Indication: Linzess (linaclotide) was approved for the treatment of irritable bowel syndrome with constipation (IBSC) and chronic idiopathic constipation (CIC) in adults. A guanylate cyclase-C agonist, Linzess should be taken on an empty stomach at least 30 minutes prior to the patient’s first meal of the day. For IBS-C, the dosage is 290 mcg orally once daily, and for CIC, the dosage is 145 mcg orally once daily. The product has a boxed warning against its use in pediatric populations.
Dosage Form: Capsules: 145 and 290 mcg
For More Information: www.linzesshcp.com



Stribild
Marketed by: Gilead Sciences, Inc (Foster City, CA)
Indication: The FDA approved Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) for the treatment of HIV-1 infection in treatment-naïve adults. The recommended dose of Stribild is 1 tablet taken once daily with food. Its packaging information specifies that it should not be initiated in patients with an estimated creatinine clearance (CrCl) less than 70 mL/min and should be discontinued in patients with an estimated CrCl less than 50 mL/min.
Dosage Form: Tablets: elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir disoproxil fumarate 300 mg
For More Information: www.stribild.com/hcp



Nucynta ER
Marketed by: Janssen Pharmaceuticals Inc (Raritan, NJ)
Indication: The FDA approved Janssen’s supplemental New Drug Application for Nucynta ER (tapentadol) extended-release oral tablets CII for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period. A Schedule II substance, Nucynta ER carries a boxed warning for its abuse potential and the risks of life-threatening respiratory depression, accidental exposure, and interaction with alcohol. It is not for as-needed use or for mild, acute, or most types of post-operative pain.
Dosage Form: Extended-release tablets: 50, 100, 150, 200, and 250 mg
For More Information: www.nucynta.com


Related Articles
Bayer HealthCare and Cardinal Health today announced the signing of a 15-year agreement for the contract manufacturing of Xofigo (radium Ra 223 dichloride). As part of the agreement, Cardinal Health will build a state-of-the art, 64,000 square foot facility in Indianapolis, which will be dedicated exclusively to the manufacturing of Xofigo. Product manufactured at this facility will primarily be distributed in the United States and Canada.
Multiple sclerosis patients are increasingly using supplements to treat their depression symptoms.
ASHP today recognized the work of the late Jerod M. Loeb, Ph.D., a tireless patient safety advocate, with the ASHP Board of Directors Award of Honor. Loeb’s widow, Sherri, accepted the award during the opening session of ASHP’s Midyear Clinical Meeting in Anaheim, CA. Dr. Loeb passed away in 2013 from metastatic prostate cancer.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$